CRISPR Therapeutics AG Common Shares (NASDAQ: CRSP) last traded at $50.22, up 0.24% on the session. The quote above updates while this page is open; the figures below are drawn from CRISPR Therapeutics AG Common Shares’s own filings and are restated only when a new one is published.
CRISPR Therapeutics AG Common Shares trades on NASDAQ under the ticker CRSP. Its market capitalisation is $4.86 billion.
Valuation measures for CRISPR Therapeutics AG Common Shares, derived from the latest quote and its most recent SEC filing.
| Market cap | $4.86B |
|---|---|
| Enterprise value | $5.47B |
| Price / sales | 362.60 |
| Price / book | 2.78 |
| Beta | 1.90 |
Trailing-twelve-month figures tagged in CRISPR Therapeutics AG Common Shares's XBRL filings with the SEC.
| Revenue (TTM) | $13.39M |
|---|---|
| Net income (TTM) | -$451.14M |
| EPS (TTM) | -$4.71 |
| Operating margin | -3989.99% |
| Return on equity | -25.83% |
| Cash | $291.34M |
Range and volume for CRSP over the past 52 weeks.
| 52-week high | $75.06 |
|---|---|
| 52-week low | $44.12 |
| Volume | 1.70M |
| Average volume | 1.59M |
| Previous close | $50.10 |
Invest a chosen dollar amount in CRISPR Therapeutics AG Common Shares with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell CRSP.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.